Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.